← Leaderboards
Sergei Zolotukhin
Johns Hopkins University
$5,763,792
Attributed
$11,242,431
Total exposure
8
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–20$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$11,242,431 · 8
By mechanism
R01$6,680,843 · 2
R42$2,456,333 · 1
P01$1,763,339 · 3
R21$289,000 · 1
K18$52,916 · 1
Top collaborators
- Roland W. Herzog9 shared
- Arun Srivastava9 shared
- Guang-Ping Gao5 shared
- David D Tran4 shared
- Darin J Falk3 shared
- Kenneth H Warrington1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Stephen C Gammie$2,988,766
- George A Ricaurte$14,201,416
- Alan R Schwartz$13,430,351
- Chi V. Dang$24,535,395
- Martin G Pomper$38,517,075
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapySerotypingAdeno-Associated Viral VectorVectorTransfection /Expression VectorIn VivoCapsidBiologyDependovirusBaseTransduction EfficiencyVirusAdeno Associated Virus GroupCellsDesignExhibitsMutationFloridaRecombinant Adeno-Associated Virus (Raav)CombinatorialClinical TrialsLibrariesLiverBiomedical Facility
Grant awards (34)
Targeting glioblastoma stem-like cells with custom-designed viral vectors$999,999
R42 · FY2020 · CA
Targeting glioblastoma stem-like cells with custom-designed viral vectors$999,999
R42 · FY2019 · CA
Targeting glioblastoma stem-like cells with custom-designed viral vectors$156,335
R42 · FY2019 · CA
Next Generation of Recombinant AAV Serotype For Gene Therapy$770,648
R01 · FY2018 · HL
Targeting glioblastoma stem-like cells with custom-designed viral vectors$300,000
R42 · FY2018 · CA
Next Generation of Recombinant AAV Serotype For Gene Therapy$788,573
R01 · FY2017 · HL
Next Generation of Recombinant AAV Serotype For Gene Therapy$622,223
R01 · FY2016 · HL
Next Generation of Recombinant AAV Serotype For Gene Therapy$142,500
R01 · FY2016 · HL
Next Generation of Recombinant AAV Serotype For Gene Therapy$630,906
R01 · FY2015 · HL
Next Generation of Recombinant AAV Serotype Vectors for Gene Therapy$593,093
R01 · FY2013 · HL
Next Generation of Recombinant AAV Serotype Vectors for Gene Therapy$613,662
R01 · FY2012 · HL
Next Generation of Recombinant AAV Serotype Vectors for Gene Therapy$597,388
R01 · FY2011 · HL
Next Generation of Recombinant AAV Serotype Vectors for Gene Therapy$633,276
R01 · FY2010 · HL
A Novel Class of Orally-Applied Inhibitors of Aggressive Behavior$52,916
K18 · FY2010 · MH · contact PI
CORE--VECTOR$113,216
P01 · FY2009 · AG · contact PI
CORE--VECTOR$109,204
P01 · FY2008 · AG · contact PI
rAAV-Mediated Metabolic Engineering in Vivo$248,329
R01 · FY2007 · DK · contact PI
CORE--VECTOR$100,184
P01 · FY2007 · AG · contact PI
rAAV-Mediated Metabolic Engineering in Vivo$255,745
R01 · FY2006 · DK · contact PI
CORE--VECTOR$70,399
P01 · FY2006 · AG · contact PI
rAAV-Mediated Metabolic Engineering in Vivo$261,900
R01 · FY2005 · DK
CORE--VECTOR$68,349
P01 · FY2005 · AG
rAAV-Mediated Metabolic Engineering in Vivo$261,600
R01 · FY2004 · DK
rAAV-Mediated Metabolic Engineering in Vivo$261,000
R01 · FY2003 · DK
CORE--VECTOR PRODUCTION$242,910
P01 · FY2002 · NS
CORE--VECTOR$0
P01 · FY2002 · HL
CORE--VECTOR PRODUCTION$283,370
P01 · FY2001 · NS
CYTOKINE GENE THERAPY AND OBESITY$144,500
R21 · FY2001 · DK
CORE--VECTOR$0
P01 · FY2001 · HL
CORE--VECTOR PRODUCTION$0
P01 · FY2001 · NS
CORE--VECTOR PRODUCTION$283,370
P01 · FY2000 · NS
CORE--VECTOR$270,973
P01 · FY2000 · HL
CORE--VECTOR PRODUCTION$221,364
P01 · FY2000 · NS
CYTOKINE GENE THERAPY AND OBESITY$144,500
R21 · FY2000 · DK